The FDA is opening a comprehensive review of its playbook for Rare Disease">rare disease Framework Initiative. Leaders say the push reflects how therapies for uncommon conditions now account for a growing slice of approvals. "This is a true approach to transform the way we review rare diseases," said Karim Mikhail, who runs the Center for Biologics Evaluation and Research that oversees cell and gene therapies.
Agency officials said this move is not a reaction to last year's disputes over rare disease decisions. During that period, some applications hit surprise rejections or delays under then commissioner Marty Makary, prompting questions from Congress, appeals to the White House, and criticism from patient groups. The FDA has not had a permanent chief since Makary departed in May; White House policy aide Heidi Overton has been nominated to lead the agency and is awaiting Senate action. Last month, Mikhail and Center for Drug Evaluation and Research Director Michael Davis were named as the permanent heads of their respective centers.
Today, patient voices are typically heard late, at advisory committee meetings after trials are finished and reviewers have largely wrapped up their analyses. Companies, meanwhile, can pour resources into studies only to clash later with the agency over what data meet the bar for approval. The new framework aims to change that by building in patient engagement earlier and at key milestones, and by giving developers steadier guidance on how decisions will be made.
The FDA said its approach should reflect the level of evidence that is realistically achievable for rare conditions. Amy Comstock Rick, the agency's point person for rare disease strategy, said the FDA should be "clear along the way," adding, "There shouldn't be surprises." Davis said the agency is trying to run this effort the right way, with input from staff across the organization rather than a top-down design. Officials also described the plan as broader than an earlier Makary-era concept known as the "plausible mechanism" pathway, which zeroed in on the very rarest disorders affecting only small numbers of patients.
Markets move for many reasons, so sign up for the free Market Briefs newsletter to get clear daily context.
The process could culminate in formal guidance or even regulations. Internally, the FDA is aiming to outline initial recommendations by February, though that could shift based on what it hears.
When policy and innovation affect long term plans, subscribe to the free Market Briefs for a short daily note you can trust.
